PLSE - Pulse Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
12.71
-0.62 (-4.65%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close13.33
Open13.27
Bid0.00 x 1100
Ask0.00 x 1300
Day's Range12.65 - 13.27
52 Week Range8.60 - 26.79
Volume15,848
Avg. Volume55,389
Market Cap215.887M
Beta (3Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-2.22
Earnings DateMar 12, 2018 - Mar 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wireyesterday

    Pulse Biosciences, Inc. Announces Commencement of Rights Offering

    Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, today announced that it has commenced its previously announced rights offering of $45,000,000 of its common stock. The subscription rights will expire and have no value if they are not exercised prior to 5:00 p.m. Eastern Time on Thursday December 6, 2018 (the “Expiration Date”). Pursuant to the rights offering, Pulse Biosciences is distributing, at no charge to the holders of its common stock, non-transferable subscription rights to purchase up to $45,000,000 of shares of its common stock at a subscription price per share equal to the lesser of (i) $13.33 per share (the “Initial Price”) or (ii) the volume weighted average price (the “Alternate Price”) of the Company’s common stock as calculated for the five-trading day period through and including the Expiration Date.

  • Business Wire5 days ago

    Pulse Biosciences Grants Equity Incentive Awards to New Employees

    Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, announced today that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 17,000 shares of Pulse Biosciences common stock to two new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on November 15, 2018.

  • Business Wire13 days ago

    Pulse Biosciences, Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of Its Registration Statement

    Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, today announced that it has set key dates and pricing structure for its previously announced rights offering of $45,000,000 of its common stock. Pulse Biosciences intends to issue non-transferable subscription rights to purchase shares of its common stock to common stockholders as of 5:00 p.m. Eastern Time on Monday November 19, 2018 (the “Record Date”).

  • GlobeNewswire19 days ago

    Report: Developing Opportunities within Pulse Biosciences, Baxter International, FirstEnergy, Affiliated Managers Group, Baidu, and Shopify — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire21 days ago

    Pulse Biosciences Quarterly Investor Conference Call

    Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT

  • Business Wire27 days ago

    Pulse Biosciences Files Registration Statement for Rights Offering

    Pulse Biosciences, Inc. (PLSE) (the “Company”, or “Pulse Biosciences”) today announced that it filed a registration statement on Form S-3 with the Securities and Exchange Commission (the “SEC”) for a rights offering to its existing stockholders. The rights offering will be made through the distribution of non-transferable subscription rights to purchase shares of the Company’s common stock, par value $0.001 per share, at a subscription price to be determined. Assuming the rights offering is fully subscribed, the Company will receive gross proceeds of approximately $45 million, less expenses of the rights offering.

  • Business Wire28 days ago

    Pulse Biosciences to Report Third Quarter 2018 and Operational Highlights and Financial Results

    Pulse Biosciences, Inc. , a novel medical therapy company bringing to market its proprietary Nano-Pulse Stimulation™ platform, today announced that the Company will report third quarter 2018 operational highlights and financial results on Tuesday, October 30, 2018.

  • Business Wirelast month

    Pulse Biosciences Grants Equity Incentive Awards to New Employees

    Pulse Biosciences, Inc. (PLSE), a novel medical therapy company bringing to market its proprietary Nano-Pulse Stimulation™ platform, announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 20,750 shares of Pulse Biosciences common stock to four new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on October 15, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual's entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • Business Wirelast month

    Pulse Biosciences Announces Continued Expansion of Its Clinical Study Programs in Dermatology

    Fourth Dermatology Study Will Evaluate Nano-Pulse Stimulation™ in Treating Cutaneous Warts

  • Simply Wall St.last month

    What Kind Of Risk Should You Expect For Pulse Biosciences Inc (NASDAQ:PLSE)?

    Anyone researching Pulse Biosciences Inc (NASDAQ:PLSE) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Read More...

  • Business Wire2 months ago

    Pulse Biosciences to Present at the Cantor Global Healthcare Conference

    Pulse Biosciences, Inc. , a novel medical therapy company bringing to market its proprietary Nano-Pulse Stimulation™ platform, announced today that Darrin Uecker, President and Chief Executive Officer, is scheduled to present at the Cantor Global Healthcare Conference in New York at 4:00 p.m.

  • Business Wire2 months ago

    Pulse Biosciences Grants Equity Incentive Awards to New Employees

    Pulse Biosciences, Inc. (PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse StimulationTM (NPSTM) platform, announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 34,250 shares of Pulse Biosciences common stock to four new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on September 17, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual's entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • Business Wire3 months ago

    Robbins Arroyo LLP Is Investigating the Officers and Directors of Pulse Biosciences, Inc. (PLSE) on Behalf of Shareholders

    Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Pulse Biosciences, Inc. breached their fiduciary duties to shareholders.

  • Business Wire4 months ago

    Pulse Biosciences Grants Equity Incentive Awards to New Employees

    Pulse Biosciences, Inc. (PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 18,250 shares of Pulse Biosciences common stock to five new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on August 3, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual's entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • Business Wire4 months ago

    Pulse Biosciences Quarterly Investor Conference Call

    Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT

  • ACCESSWIRE4 months ago

    Pulse Biosciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Pulse Biosciences, Inc. (NASDAQ: PLSE ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 31, 2018 at 4:30 PM Eastern Time. ...

  • Business Wire4 months ago

    Pulse Biosciences Treats Initial Patient in Its Human Study Evaluating the Effects of Nano-Pulse Stimulation in Basal Cell Carcinoma

    Pulse Biosciences, Inc. (PLSE) today announced the treatment of the first patient in a clinical study to evaluate Nano-Pulse Stimulation (NPS) in a common skin cancer, Basal Cell Carcinoma (BCC). Patients in the study will be treated with NPS prior to resection of the BCC lesion, which is the standard of care for BCC lesions. Post resection tissue samples will be assessed for elimination of the BCC lesion in the NPS treatment zone and for biomarkers indicating an immune response to the NPS-treated BCC lesions.

  • Business Wire4 months ago

    Pulse Biosciences to Report Second Quarter 2018 Financial Results and Operational Highlights

    Pulse Biosciences, Inc. , a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation platform, today announced that the Company will report second quarter 2018 operational highlights and financial results on Tuesday, July 31, 2018.

  • Business Wire4 months ago

    Pulse Biosciences Announces Treatment of First Patients in Study to Evaluate the Safety and Efficacy of Novel Nano-Pulse Stimulation for the Treatment of Sebaceous Hyperplasia Lesions

    Pulse Biosciences, Inc. (PLSE) today announced treatment of the first patients in its multicenter study to evaluate the safety and efficacy of its Nano-Pulse Stimulation (NPS) technology for eliminating Sebaceous Hyperplasia (SH), an unsightly benign skin lesion that typically appears on facial skin and is considered a difficult-to-treat condition with current modalities. NPS is a non-thermal technology that utilizes ultra-short, nanosecond pulsed electrical fields to directly affect cell membranes and intracellular structures while sparing non-cellular tissues.

  • Business Wire5 months ago

    Robbins Arroyo LLP Is Investigating the Officers and Directors of Pulse Biosciences, Inc. (PLSE) on Behalf of Shareholders

    Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Pulse Biosciences, Inc. breached their fiduciary duties to shareholders.

  • Business Wire5 months ago

    Pulse Biosciences Grants Equity Incentive Awards to New Employees

    Pulse Biosciences, Inc. (PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 30,000 shares of Pulse Biosciences common stock to two new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on June 22, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual's entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • ACCESSWIRE5 months ago

    Kaskela Law LLC Announces Investigation of Pulse Biosciences, Inc. on Behalf of Stockholders

    RADNOR, PA / ACCESSWIRE / June 20, 2018 / Kaskela Law LLC is investigating Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE) on behalf of the Company's stockholders. ...

  • Business Wire6 months ago

    Pulse Biosciences Grants Equity Incentive Awards to New Employees

    Pulse Biosciences, Inc. (PLSE) (the “Company” or “Pulse Biosciences”), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, announced today that the Compensation Committee of the Company’s Board of Directors (the “Board”) granted non-qualified stock options covering an aggregate of 102,000 shares of Pulse Biosciences common stock to three new employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on May 15, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual's entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • Business Wire6 months ago

    Pulse Biosciences Quarterly Investor Conference Call

    Pulse Biosciences, Inc. , a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation platform, today reported recent corporate developments and financial results for the first quarter ended March 31, 2018.

  • Business Wire7 months ago

    Pulse Biosciences to Report First Quarter 2018 Financial Results and Operational Highlights

    Pulse Biosciences, Inc. , a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation platform, today announced that the Company will report first quarter 2018 financial results and operational highlights on Tuesday, May 8, 2018.